Home > Research > Publications & Outputs > A randomised, double-blind trial of valaciclovi...

Research

Electronic data

Links

Text available via DOI:

View graph of relations

A randomised, double-blind trial of valaciclovir prophylaxis for cytomegalovirus disease in patients with advanced human immunodeficiency virus infection.

Research output: Contribution to Journal/Magazine › Journal article › peer-review

Published

Standard

A randomised, double-blind trial of valaciclovir prophylaxis for cytomegalovirus disease in patients with advanced human immunodeficiency virus infection. / Feinburg, Judith E.; Hurwitz, Shelley; Cooper, David et al.
In: Journal of Infectious Diseases, Vol. 177, No. 1, 01.1998, p. 48-56.

Research output: Contribution to Journal/Magazine › Journal article › peer-review

Harvard

Feinburg, JE, Hurwitz, S, Cooper, D, Sattler, FR, Macgregor, RR, Holland, GN, Griffiths, PD, Pollard, R, Youle, M, Gill, MJ, Holland, FJ & et al 1998, 'A randomised, double-blind trial of valaciclovir prophylaxis for cytomegalovirus disease in patients with advanced human immunodeficiency virus infection.', Journal of Infectious Diseases, vol. 177, no. 1, pp. 48-56. https://doi.org/10.1086/513804

APA

Feinburg, J. E., Hurwitz, S., Cooper, D., Sattler, F. R., Macgregor, R. R., Holland, G. N., Griffiths, P. D., Pollard, R., Youle, M., Gill, M. J., Holland, F. J., & et al, . (1998). A randomised, double-blind trial of valaciclovir prophylaxis for cytomegalovirus disease in patients with advanced human immunodeficiency virus infection. Journal of Infectious Diseases, 177(1), 48-56. https://doi.org/10.1086/513804

Vancouver

Feinburg JE, Hurwitz S, Cooper D, Sattler FR, Macgregor RR, Holland GN et al. A randomised, double-blind trial of valaciclovir prophylaxis for cytomegalovirus disease in patients with advanced human immunodeficiency virus infection. Journal of Infectious Diseases. 1998 Jan;177(1):48-56. doi: 10.1086/513804

Author

Feinburg, Judith E. ; Hurwitz, Shelley ; Cooper, David et al. / A randomised, double-blind trial of valaciclovir prophylaxis for cytomegalovirus disease in patients with advanced human immunodeficiency virus infection. In: Journal of Infectious Diseases. 1998 ; Vol. 177, No. 1. pp. 48-56.

Bibtex

@article{008f66bd71bd46abae0dbe4f458dab2f,
title = "A randomised, double-blind trial of valaciclovir prophylaxis for cytomegalovirus disease in patients with advanced human immunodeficiency virus infection.",
abstract = "Cytomegalovirus (CMV) disease is a common complication of advanced human immunodeficiency virus (HIV) infection. Administration of oral valaciclovir, a valine ester of acyclovir, achieves sufficient plasma acyclovir levels to inhibit many clinical isolates. Acyclovir has been associated with enhanced survival in AIDS but not with CMV disease prevention. CMV-seropositive patients (1227) with CD4 cell counts <100/mm3 were enrolled in a randomized, double-blind trial. Valaciclovir, 8 g/day, was compared with acyclovir, 3.2 or 0.8 g/day, for CMV prevention; all three arms were compared for survival. The confirmed CMV disease rate was 11.7% among valaciclovir recipients and 17.5% in the pooled acyclovir arms, a 33% reduction in risk. Time to confirmed CMV disease was significantly longer for the valaciclovir group (P = .03). A trend toward earlier mortality for valaciclovir recipients was seen (P = .06). Toxicity and earlier medication discontinuation were more common in this group. Valaciclovir significantly reduces the risk of CMV disease. Further exploration of a better-tolerated dose is warranted.",
author = "Feinburg, {Judith E.} and Shelley Hurwitz and David Cooper and Sattler, {Fred R.} and Macgregor, {Rob Roy} and Holland, {Gary N.} and Griffiths, {Paul D.} and Richard Pollard and Michael Youle and Gill, {M. John} and Holland, {Fiona J} and {et al}, .",
note = "{\textcopyright} University of Chicago Press 1998",
year = "1998",
month = jan,
doi = "10.1086/513804",
language = "English",
volume = "177",
pages = "48--56",
journal = "Journal of Infectious Diseases",
issn = "0022-1899",
publisher = "Oxford University Press",
number = "1",

}

RIS

TY - JOUR

T1 - A randomised, double-blind trial of valaciclovir prophylaxis for cytomegalovirus disease in patients with advanced human immunodeficiency virus infection.

AU - Feinburg, Judith E.

AU - Hurwitz, Shelley

AU - Cooper, David

AU - Sattler, Fred R.

AU - Macgregor, Rob Roy

AU - Holland, Gary N.

AU - Griffiths, Paul D.

AU - Pollard, Richard

AU - Youle, Michael

AU - Gill, M. John

AU - Holland, Fiona J

AU - et al, .

N1 - © University of Chicago Press 1998

PY - 1998/1

Y1 - 1998/1

N2 - Cytomegalovirus (CMV) disease is a common complication of advanced human immunodeficiency virus (HIV) infection. Administration of oral valaciclovir, a valine ester of acyclovir, achieves sufficient plasma acyclovir levels to inhibit many clinical isolates. Acyclovir has been associated with enhanced survival in AIDS but not with CMV disease prevention. CMV-seropositive patients (1227) with CD4 cell counts <100/mm3 were enrolled in a randomized, double-blind trial. Valaciclovir, 8 g/day, was compared with acyclovir, 3.2 or 0.8 g/day, for CMV prevention; all three arms were compared for survival. The confirmed CMV disease rate was 11.7% among valaciclovir recipients and 17.5% in the pooled acyclovir arms, a 33% reduction in risk. Time to confirmed CMV disease was significantly longer for the valaciclovir group (P = .03). A trend toward earlier mortality for valaciclovir recipients was seen (P = .06). Toxicity and earlier medication discontinuation were more common in this group. Valaciclovir significantly reduces the risk of CMV disease. Further exploration of a better-tolerated dose is warranted.

AB - Cytomegalovirus (CMV) disease is a common complication of advanced human immunodeficiency virus (HIV) infection. Administration of oral valaciclovir, a valine ester of acyclovir, achieves sufficient plasma acyclovir levels to inhibit many clinical isolates. Acyclovir has been associated with enhanced survival in AIDS but not with CMV disease prevention. CMV-seropositive patients (1227) with CD4 cell counts <100/mm3 were enrolled in a randomized, double-blind trial. Valaciclovir, 8 g/day, was compared with acyclovir, 3.2 or 0.8 g/day, for CMV prevention; all three arms were compared for survival. The confirmed CMV disease rate was 11.7% among valaciclovir recipients and 17.5% in the pooled acyclovir arms, a 33% reduction in risk. Time to confirmed CMV disease was significantly longer for the valaciclovir group (P = .03). A trend toward earlier mortality for valaciclovir recipients was seen (P = .06). Toxicity and earlier medication discontinuation were more common in this group. Valaciclovir significantly reduces the risk of CMV disease. Further exploration of a better-tolerated dose is warranted.

U2 - 10.1086/513804

DO - 10.1086/513804

M3 - Journal article

VL - 177

SP - 48

EP - 56

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

SN - 0022-1899

IS - 1

ER -